Literature DB >> 10888639

Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1.

S E Kuhmann1, E J Platt, S L Kozak, D Kabat.   

Abstract

In addition to the primary cell surface receptor CD4, CCR5 or another coreceptor is necessary for infections by human immunodeficiency virus type 1 (HIV-1), yet the mechanisms of coreceptor function and their stoichiometries in the infection pathway remain substantially unknown. To address these issues, we studied the effects of CCR5 concentrations on HIV-1 infections using wild-type CCR5 and two attenuated mutant CCR5s, one with the mutation Y14N at a critical tyrosine sulfation site in the amino terminus and one with the mutation G163R in extracellular loop 2. The Y14N mutation converted a YYT sequence at positions 14 to 16 to an NYT consensus site for N-linked glycosylation, and the mutant protein was shown to be glycosylated at that position. The relationships between HIV-1 infectivity values and CCR5 concentrations took the form of sigmoidal (S-shaped) curves, which were dramatically altered in different ways by these mutations. Both mutations shifted the curves by factors of approximately 30- to 150-fold along the CCR5 concentration axis, consistent with evidence that they reduce affinities of virus for the coreceptor. In addition, the Y14N mutation specifically reduced the maximum efficiencies of infection that could be obtained at saturating CCR5 concentrations. The sigmoidal curves for all R5 HIV-1 isolates were quantitatively consistent with a simple mathematical model, implying that CCR5s reversibly associate with cell surface HIV-1 in a concentration-dependent manner, that approximately four to six CCR5s assemble around the virus to form a complex needed for infection, and that both mutations inhibit assembly of this complex but only the Y14N mutation also significantly reduces its ability to successfully mediate HIV-1 infections. Although several alternative models would be compatible with our data, a common feature of these alternatives is the cooperation of multiple CCR5s in the HIV-1 infection pathway. This cooperativity will need to be considered in future studies to address in detail the mechanism of CCR5-mediated HIV-1 membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888639      PMCID: PMC112217          DOI: 10.1128/jvi.74.15.7005-7015.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages.

Authors:  B Lee; M Sharron; L J Montaner; D Weissman; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Physics of chemoreception.

Authors:  H C Berg; E M Purcell
Journal:  Biophys J       Date:  1977-11       Impact factor: 4.033

3.  The organization of the envelope projections on the surface of HIV.

Authors:  M Ozel; G Pauli; H R Gelderblom
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity.

Authors:  C Blanpain; B Lee; J Vakili; B J Doranz; C Govaerts; I Migeotte; M Sharron; V Dupriez; G Vassart; R W Doms; M Parmentier
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

5.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Constitutive cell surface association between CD4 and CCR5.

Authors:  X Xiao; L Wu; T S Stantchev; Y R Feng; S Ugolini; H Chen; Z Shen; J L Riley; C C Broder; Q J Sattentau; D S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 8.  Morphogenesis and morphology of HIV. Structure-function relations.

Authors:  H R Gelderblom; M Ozel; G Pauli
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; S R Conley; J P Moore; J L Raina; H Renz; H R Gelderblom; P L Nara
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

10.  HIV requires multiple gp120 molecules for CD4-mediated infection.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; P L Nara
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  115 in total

1.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 3.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

4.  A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors.

Authors:  T L Hoffman; G Canziani; L Jia; J Rucker; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

5.  Localization of CD4 and CCR5 in living cells.

Authors:  Carolyn M Steffens; Thomas J Hope
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

7.  Viral infection: Moving through complex and dynamic cell-membrane structures.

Authors:  Jonathan Barroso-González; Laura García-Expósito; Julià Blanco; Agustín Valenzuela-Fernández; Isabel Puigdomènech; Laura de Armas-Rillo; José-David Machado
Journal:  Commun Integr Biol       Date:  2011-07-01

8.  Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.

Authors:  Mireille Guyader; Etsuko Kiyokawa; Laurence Abrami; Priscilla Turelli; Didier Trono
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.